ArticleDigestive diseases and sciences2010
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure.
Article in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Urantide alleviates lipopolysaccharide/D-galactosamine-induced acute liver failure through upregulating carboxylesterase1f in mice.Frontiers in cellular and infection microbiology · 2025Article
- Urantide prevents CCl4‑induced acute liver injury in rats by regulating the MAPK signalling pathway.Molecular medicine reports · 2021Article
- Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CClFrontiers of medicine · 2019Article
- IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure.Oncotarget · 2016Article
- Effects of urotensin-II on cytokines in early acute liver failure in mice.World journal of gastroenterology · 2015Article
- Article
- Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUrotensin II [U-II] plasma levels are increased in liver cirrhosis [LC] and are discussed as an important mediator of portal hypertension since the U-II antagonist palosuran has beneficial effects on portal hypertension by increasing splanchnic resistance. Nevertheless, no data are available on the intrahepatic expression of U-II and its receptor [UT] in humans.
methodsU-II and UT expression were analyzed in the livers of patients with LC, fulminant hepatic failure [FHF], and normal controls [NC] using immunohistochemistry.
resultsBoth U-II and UT were expressed in the liver on endothelial cells from arteries, veins, and bile ducts as well as on Kupffer cells. In LC, the total number of U-II-expressing cells was 20% lower compared to NC (P < 0.001), while expression of UT did not differ between LC and NC. In contrast, significant enhanced number of U-II and UT positive cells were found in FHF compared to LC and NC (P < 0.001). U-II and UT expression was also found in portal veins, without differences between LC and NC.
conclusionsOur data demonstrate that U-II and UT are not elevated in human cirrhotic livers but are in livers of patients with FHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.